Inflammatory regulation of glucocorticoid metabolism in mesenchymal stromal cells

Arthritis and Rheumatism

Volumn 64, Issue 7, 2012, Pages 2404-2413

  Ahasan, Mohammad M ^a,b   Hardy, Rowan ^b   Jones, Christopher ^b   Kaur, Kirren ^b   Nanus, Dominika ^b   Juarez, Maria ^b   Morgan, Stuart A ^b   Hassan Smith, Zaki ^b   Bénézech, Cécile ^b   Caamaño, Jorge H ^b   Hewison, Martin ^c   Lavery, Gareth ^b   Rabbitt, Elizabeth H ^b   Clark, Andrew R ^d   Filer, Andrew ^b   Buckley, Christopher D ^b   Raza, Karim ^b   Stewart, Paul M ^b   Cooper, Mark S ^b  

^a Research and Development   (Bangladesh)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c JOINT REPLACEMENT INSTITUTE   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; COMPLEMENTARY DNA; CYTOKINE; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST; GENE DELETION; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; MOLECULAR MECHANICS; MYOPATHY; OBESITY; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CYTOKINES; FIBROBLASTS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MESENCHYMAL STROMAL CELLS; MICE; NF-KAPPA B; OSTEOARTHRITIS; SYNOVIAL MEMBRANE;

EID: 84863207913     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34414     Document Type: Article

References (35)

1. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727-34. (Pubitemid 36237043)
2. Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984;310:1415-21. (Pubitemid 14101296)
3. Lazar G Jr, Lazar G, Agarwal MK. Modification of septic shock in mice by the antiglucocorticoid RU 38486. Circ Shock 1992;36:180-4.
4. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, et al. 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004;25:831-66. (Pubitemid 39366049)
5. Cooper MS, Stewart PM. 11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009;94:4645-54.
6. Fernandez-Rodriguez E, Stewart PM, Cooper MS. The pituitary-adrenal axis and body composition. Pituitary 2009;12:105-15.
7. Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, et al. Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001;16:1037-44. (Pubitemid 32467147)
8. Hardy R, Rabbitt EH, Filer A, Emery P, Hewison M, Stewart PM, et al. Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis 2008;67:1204-10.
9. Tiganescu A, Walker EA, Hardy RS, Mayes AE, Stewart PM. Localization, age- and site-dependent expression, and regulation of 11β-hydroxysteroid dehydrogenase type 1 in skin. J Invest Dermatol 2011;131:30-6.
10. Tomlinson JW, Moore J, Cooper MS, Bujalska I, Shahmanesh M, Burt C, et al. Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 2001;142:1982-9. (Pubitemid 32405956)
11. Morgan SA, Sherlock M, Gathercole LL, Lavery GG, Lenaghan C, Bujalska IJ, et al. 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009;58:2506-15.
12. Hardy RS, Filer A, Cooper MS, Parsonage G, Raza K, Hardie DL, et al. Differential expression, function and response to inflammatory stimuli of 11β-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Res Ther 2006;8:R108.
13. Kaur K, Hardy R, Ahasan MM, Eijken M, van Leeuwen JP, Filer A, et al. Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Ann Rheum Dis 2010;69:1185-90.
14. Thieringer R, le Grand CB, Carbin L, Cai TQ, Wong B, Wright SD, et al. 11β-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol 2001;167:30-5. (Pubitemid 32567757)
15. Hennebold JD, Ryu SY, Mu HH, Galbraith A, Daynes RA. 11β- hydroxysteroid dehydrogenase modulation of glucocorticoid activities in lymphoid organs. Am J Physiol 1996;270:R1296-306.
16. Raza K, Hardy R, Cooper MS. The 11β-hydroxysteroid dehydrogenase enzymes-arbiters of the effects of glucocorticoids in synovium and bone. Rheumatology (Oxford) 2010;49:2016-23.
17. Williams LJ, Lyons V, Wallace R, Seckl JR, Chapman KE. CCAAT/enhancer binding protein positively regulates the rat 11β-hydroxysteroid dehydrogenase type 1 promoter in liver cells. Biochem Soc Trans 1997;25:235S.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
19. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck RP, et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 1995;80:331-40.
20. Caamano JH, Rizzo CA, Durham SK, Barton DS, Raventos- Suarez C, Snapper CM, et al. Nuclear factor (NF)-κB2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med 1998;187:185-96. (Pubitemid 28060434)
21. Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 1996;13:925-31. (Pubitemid 26329078)
22. Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM. Expression and functional consequences of 11β-hydroxysteroid dehydrogenase activity in human bone. Bone 2000;27:375-81. (Pubitemid 30658120)
23. Eijken M, Hewison M, Cooper MS, de Jong FH, Chiba H, Stewart PM, et al. 11β-hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. Mol Endocrinol 2005;19:621-31. (Pubitemid 40349436)
24. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005;353:1711-23.
25. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995;270:286-90.
26. De Bosscher K, vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003;24:488-522. (Pubitemid 37059110)
27. Engelbrecht Y, de Wet H, Horsch K, Langeveldt CR, Hough FS, Hulley PA. Glucocorticoids induce rapid up-regulation of mitogen- activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines. Endocrinology 2003;144:412-22. (Pubitemid 36205211)
28. Horsch K, de Wet H, Schuurmans MM, Allie-Reid F, Cato AC, Cunningham J, et al. Mitogen-activated protein kinase phosphatase 1/dual specificity phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol Endocrinol 2007;21:2929-40. (Pubitemid 350225576)
29. Rebholz B, Haase I, Eckelt B, Paxian S, Flaig MJ, Ghoreschi K, et al. Crosstalk between keratinocytes and adaptive immune cells in an IκBα protein-mediated inflammatory disease of the skin. Immunity 2007;27:296-307. (Pubitemid 47284918)
30. Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 2010;11:517-31.
31. Gossye V, Elewaut D, Bougarne N, Bracke D, van Calenbergh S, Haegeman G, et al. Differential mechanism of NF-κB inhibition by two glucocorticoid receptor modulators in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009;60:3241-50.
32. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM. Osteoblastic 11β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 2002;17:979-86. (Pubitemid 34535135)
33. Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS, et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006;54:463-72. (Pubitemid 43228620)
34. Boyle CD, Kowalski TJ. 11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Expert Opin Ther Pat 2009;19:801-25.
35. Chapman KE, Coutinho AE, Gray M, Gilmour JS, Savill JS, Seckl JR. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol Cell Endocrinol 2009;301:123-31.